Skip to main content
NVCT
NASDAQ Life Sciences

Nuvectis Q2: $115M Raise Closes, Haisco Deal Activated, NXP100 Approved in China

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$18.5
Mkt Cap
$680.952M
52W Low
$5.55
52W High
$29.275
52W Position info
233% above low
Off High info
37% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NVCT has more than doubled off its 52-week low of $5.55.

Summary

Nuvectis closed a $115M offering, activated the Haisco license, and reported NXP100's Chinese approval — transforming its pipeline and balance sheet in a single quarter.


Key Events · Earnings and Guidance · NVCT

  • $115M Follow-On Offering Closed

    Completed sale of 5.75M shares at $20.00 each, generating $106.3M in net proceeds. The offering, which included full exercise of the underwriters' option, strengthens the balance sheet and funds the Haisco upfront payment and pipeline development.

  • Haisco License Effective; $20M Upfront Paid

    The exclusive license for NXP100 and NXP200 became effective July 1, 2026, upon closing of the offering. Nuvectis paid Haisco a $20.0 million upfront fee and gained ex-China rights to two clinical-stage assets.

  • NXP100 Approved in China for PNH

    Ciprocopan (NXP100) received marketing approval from China's NMPA for treatment-naive paroxysmal nocturnal hemoglobinuria, marking the first regulatory approval for a Nuvectis pipeline candidate.

  • Q2 Net Loss Widens to $7.0M

    Net loss increased to $7.0M from $6.3M a year ago, driven by a 30% rise in R&D expenses to $4.7M, primarily for NXP900 clinical trials and manufacturing. G&A declined 16% to $2.5M.


Analysis · NVCT · Life Sciences

Nuvectis Pharma's Q2 2026 10-Q confirms the closing of a $115 million follow-on offering, the effectiveness of the Haisco license for NXP100 and NXP200, and the first marketing approval for NXP100 in China. The offering, priced at $20.00 per share, brought in net proceeds of $106.3 million, extending the cash runway to at least 12 months. The Haisco deal became effective July 1, triggering a $20 million upfront payment. NXP100's Chinese approval for treatment-naive PNH validates the asset, though U.S. and EU approvals remain uncertain. The company reported a $7.0 million net loss for Q2, with R&D spend rising 30% year-over-year to $4.7 million, reflecting increased clinical activity. With $22.2 million in cash at quarter-end and the new capital, Nuvectis is funded to advance its pipeline, but will need additional financing to complete later-stage trials.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCT was trading at $18.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $681M. The 52-week trading range was $5.55 to $29.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCT - Latest Insights

NVCT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.42
Real-time Price: $19.50 info
Change: +$0.080 (+0.41%) info
Market Cap: $657.172M info
NVCT
Nov 04, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $19.50 info
Change: +$0.160 (+0.83%) info
Market Cap: $657.172M info
NVCT
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $19.50 info
Change: +$0.160 (+0.83%) info
Market Cap: $657.172M info
NVCT
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.05
Real-time Price: $19.50 info
Change: -$0.550 (-3%) info
Market Cap: $657.172M info
NVCT
Sep 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $19.50 info
Change: -$2.20 (-10%) info
Market Cap: $657.172M info